title: Ischemic complications after percutaneous transluminal coronary angioplasty.
abstract: The ischemic complications ofpercutaneous transluminal coronary angioplasty (PTCA) include abrupt closure, which occurs in 2% to 10% of patients and is associated with increased morbidity and mortality. Periprocedural myocardial infarction due to side branch occlusion or embolization of platelet aggregates or thrombus occurs in 5% to 20% of patients. Patients with acute coronary syndromes, older age, and complex lesions are at greater risk of periprocedural complications. Technical advances, primarily stenting, are useful in the prevention and management of acute closure, but are also accompanied by thrombotic complications. It remains to be seen whether the new antithrombin agents reduce the rate of periprocedural complications if used in combination with aspirin and new antiplatelet therapies. These new antiplatelet agents (ticlopidine, clopidogrel, abciximab, eptifibatide, and tirofiban) reduce the rate of ischemic complications and have become standard adjunctive therapy for patients who undergo PTCA.
authors.affiliation: Department of Medicine, Division of Cardiology, University of Michigan, Ann Arbor, USA.
authors.forename: E R
authors.initials: ER
authors.lastname: Bates
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects*; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D009203:Myocardial Infarction / Q000209:etiology; D017202:Myocardial Ischemia / Q000209:etiology* / Q000517:prevention & control*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D015607:Stents
chemical_list: D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors